Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04972968




Registration number
NCT04972968
Ethics application status
Date submitted
13/07/2021
Date registered
22/07/2021
Date last updated
15/10/2024

Titles & IDs
Public title
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
Scientific title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment
Secondary ID [1] 0 0
2021-000648-23
Secondary ID [2] 0 0
M20-370
Universal Trial Number (UTN)
Trial acronym
AIM-PMR
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Polymyalgia Rheumatica 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Neurological 0 0 0 0
Other neurological disorders
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ABBV-154
Treatment: Drugs - Placebo
Treatment: Drugs - Glucocorticoid

Experimental: ABBV-154 Dose A - Participants in this group will receive dose A of ABBV-154 subcutaneously (SC) every other week (eow) for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.

Experimental: ABBV-154 Dose B - Participants in this group will receive dose B of ABBV-154 SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.

Experimental: ABBV-154 Dose C - Participants in this group will receive dose C of ABBV-154 SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.

Placebo comparator: Placebo - Participants will receive placebo SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.


Treatment: Drugs: ABBV-154
Subcutaneous Injection

Treatment: Drugs: Placebo
Subcutaneous Injection

Treatment: Drugs: Glucocorticoid
Oral Tablet
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to Flare
Timepoint [1] 0 0
From first dose of study drug to Week 52
Secondary outcome [1] 0 0
Percentage of Participants Achieving Flare-Free State
Timepoint [1] 0 0
Up to Week 24
Secondary outcome [2] 0 0
Cumulative Glucocorticoid Dose
Timepoint [2] 0 0
Week 24
Secondary outcome [3] 0 0
Change From Baseline in Glucocorticoid Dose
Timepoint [3] 0 0
Week 24

Eligibility
Key inclusion criteria
* Clinical diagnosis of Polymyalgia Rheumatica (PMR) and fulfillment of the 2012 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) provisional classification criteria for PMR.
* Must have had at least 2 episodes of unequivocal PMR flare.
* Must be on a stable dose of prednisone.
* Must be willing to follow the protocol-defined glucocorticoid tapering regimen.
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Have been treated with a prior TNF antagonist.
* Current use of immunomodulators other than prednisone and hydroxychloroquine.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/09/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
24/07/2023
Sample size
Target
Accrual to date
Final
181
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Emeritus Research Sydney /ID# 229166 - Botany
Recruitment hospital [2] 0 0
Royal Prince Alfred Hospital /ID# 244888 - Camperdown
Recruitment hospital [3] 0 0
BJC Health /ID# 244839 - Paramatta
Recruitment hospital [4] 0 0
Tasman Health Care /ID# 230829 - Southport
Recruitment hospital [5] 0 0
The Queen Elizabeth Hospital /ID# 229049 - Woodville South
Recruitment hospital [6] 0 0
Emeritus Research /ID# 229270 - Camberwell
Recruitment hospital [7] 0 0
Austin Health /ID# 229164 - Heidelberg
Recruitment hospital [8] 0 0
Fiona Stanley Hospital /ID# 229050 - Murdoch
Recruitment postcode(s) [1] 0 0
2019 - Botany
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
2150 - Paramatta
Recruitment postcode(s) [4] 0 0
4215 - Southport
Recruitment postcode(s) [5] 0 0
5011 - Woodville South
Recruitment postcode(s) [6] 0 0
3124 - Camberwell
Recruitment postcode(s) [7] 0 0
3084 - Heidelberg
Recruitment postcode(s) [8] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Delaware
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Mississippi
Country [9] 0 0
United States of America
State/province [9] 0 0
New Hampshire
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
South Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Tennessee
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
Austria
State/province [17] 0 0
Wien
Country [18] 0 0
Canada
State/province [18] 0 0
Alberta
Country [19] 0 0
Canada
State/province [19] 0 0
Ontario
Country [20] 0 0
Canada
State/province [20] 0 0
Quebec
Country [21] 0 0
France
State/province [21] 0 0
Doubs
Country [22] 0 0
France
State/province [22] 0 0
Finistere
Country [23] 0 0
France
State/province [23] 0 0
Herault
Country [24] 0 0
France
State/province [24] 0 0
Sarthe
Country [25] 0 0
France
State/province [25] 0 0
Chambray Les Tours
Country [26] 0 0
France
State/province [26] 0 0
Paris
Country [27] 0 0
Germany
State/province [27] 0 0
Baden-Wuerttemberg
Country [28] 0 0
Germany
State/province [28] 0 0
Berlin-buch
Country [29] 0 0
Germany
State/province [29] 0 0
Berlin
Country [30] 0 0
Germany
State/province [30] 0 0
Hamburg
Country [31] 0 0
Germany
State/province [31] 0 0
Ratingen
Country [32] 0 0
Hungary
State/province [32] 0 0
Hajdu-Bihar
Country [33] 0 0
Hungary
State/province [33] 0 0
Zala
Country [34] 0 0
Hungary
State/province [34] 0 0
Budapest
Country [35] 0 0
Hungary
State/province [35] 0 0
Gyula
Country [36] 0 0
Hungary
State/province [36] 0 0
Kistarcsa
Country [37] 0 0
Hungary
State/province [37] 0 0
Szekesfehervar
Country [38] 0 0
Hungary
State/province [38] 0 0
Szentes
Country [39] 0 0
Hungary
State/province [39] 0 0
Veszprém
Country [40] 0 0
Italy
State/province [40] 0 0
Genova
Country [41] 0 0
Italy
State/province [41] 0 0
Torino
Country [42] 0 0
Italy
State/province [42] 0 0
Modena
Country [43] 0 0
Italy
State/province [43] 0 0
Pavia
Country [44] 0 0
Italy
State/province [44] 0 0
Siena
Country [45] 0 0
Italy
State/province [45] 0 0
Udine
Country [46] 0 0
Japan
State/province [46] 0 0
Aichi
Country [47] 0 0
Japan
State/province [47] 0 0
Chiba
Country [48] 0 0
Japan
State/province [48] 0 0
Ehime
Country [49] 0 0
Japan
State/province [49] 0 0
Kagawa
Country [50] 0 0
Japan
State/province [50] 0 0
Mie
Country [51] 0 0
Japan
State/province [51] 0 0
Oita
Country [52] 0 0
Japan
State/province [52] 0 0
Okayama
Country [53] 0 0
Japan
State/province [53] 0 0
Osaka
Country [54] 0 0
Japan
State/province [54] 0 0
Tokyo
Country [55] 0 0
Japan
State/province [55] 0 0
Toyama
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Seoul Teugbyeolsi
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Daegu
Country [58] 0 0
Netherlands
State/province [58] 0 0
Almelo
Country [59] 0 0
Netherlands
State/province [59] 0 0
Groningen
Country [60] 0 0
Netherlands
State/province [60] 0 0
Leeuwarden
Country [61] 0 0
Netherlands
State/province [61] 0 0
Maastricht
Country [62] 0 0
Netherlands
State/province [62] 0 0
Rotterdam
Country [63] 0 0
New Zealand
State/province [63] 0 0
Auckland
Country [64] 0 0
New Zealand
State/province [64] 0 0
Canterbury
Country [65] 0 0
New Zealand
State/province [65] 0 0
Waikato
Country [66] 0 0
New Zealand
State/province [66] 0 0
Wellington
Country [67] 0 0
New Zealand
State/province [67] 0 0
Christchurch Central
Country [68] 0 0
Poland
State/province [68] 0 0
Dolnoslaskie
Country [69] 0 0
Poland
State/province [69] 0 0
Kujawsko-pomorskie
Country [70] 0 0
Poland
State/province [70] 0 0
Mazowieckie
Country [71] 0 0
Poland
State/province [71] 0 0
Podlaskie
Country [72] 0 0
Poland
State/province [72] 0 0
Wielkopolskie
Country [73] 0 0
Spain
State/province [73] 0 0
A Coruna
Country [74] 0 0
Spain
State/province [74] 0 0
Barcelona
Country [75] 0 0
Spain
State/province [75] 0 0
Cantabria
Country [76] 0 0
Spain
State/province [76] 0 0
Santa Cruz De Tenerife
Country [77] 0 0
Spain
State/province [77] 0 0
Madrid
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Cambridgeshire
Country [79] 0 0
United Kingdom
State/province [79] 0 0
England
Country [80] 0 0
United Kingdom
State/province [80] 0 0
London, City Of
Country [81] 0 0
United Kingdom
State/province [81] 0 0
Norfolk
Country [82] 0 0
United Kingdom
State/province [82] 0 0
Wales
Country [83] 0 0
United Kingdom
State/province [83] 0 0
Coventry
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Edinburgh
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Liverpool
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Portsmouth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Polymyalgia rheumatica (PMR) is an inflammatory disease causing shoulder, hip, and neck pain and stiffness, in adults aged 50 years or older. This study evaluates how safe and effective ABBV-154 is in participants with glucocorticoid-dependent PMR. Adverse events and change in disease activity will be assessed.

ABBV-154 is an investigational drug being evaluated for the treatment of PMR. Participants will be randomized into 1 of 4 treatment groups or arms, each arm receiving a different treatment. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 participants, of at least 50 years of age, with PMR will be enrolled in the study at approximately 95 sites worldwide.

The study is compromised of a 52 week double-blind, placebo-controlled period and a follow-up visit 70 days after the last dose of the study drug. All participants will receive a glucocorticoid taper along with the assigned dose of ABBV-154 or placebo, subcutaneously (SC) every other week (eow).

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Trial website
https://clinicaltrials.gov/study/NCT04972968
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04972968